Home/Larimar Therapeutics/Andrew I. Sassine, J.D.
AI

Andrew I. Sassine, J.D.

Director

Larimar Therapeutics

Larimar Therapeutics Pipeline

DrugIndicationPhase
CTI-1601 (Nomaxofusp)Friedreich's AtaxiaPhase 2
CTI-1601Friedreich's AtaxiaPhase 1